Specificity in cancer immunotherapy

Seminars in Immunology

Volumn 20, Issue 5, 2008, Pages 276-285

  Schietinger, Andrea ^a   Philip, Mary ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer immunotherapy; Cosmc; Glycosylation; Specificity; Tumor antigens

Indexed keywords

CHAPERONE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; GLYCOSYLATION; MUTATION; PROTEIN ANALYSIS; PROTEIN MODIFICATION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 55549130240     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2008.07.001     Document Type: Review

References (137)

1. Schreiber H. In: Paul W. (Ed). Fundamental Immunology. 5th ed. (2003), Lippincott-Williams & Wilkins 1557-1592
2. Dermime S., Gilham D.E., Shaw D.M., Davidson E.J., Meziane el K., Armstrong A., et al. Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 1704 1 (2004) 11-35
3. Oettgen H.F., Rettig W.J., Lloyd K.O., and Old L.J. Serologic analysis of human cancer. Immunol Allergy Clin North Am 10 4 (1990) 607-637
4. Lloyd K.O. Molecular characteristics of tumor antigens. Immunol Allergy Clin North Am 10 4 (1990) 765-779
5. Furukawa K.S., Furukawa K., Real F.X., Old L.J., and Lloyd K.O. A unique antigenic epitope of human melanoma is carried on the common melanoma glycoprotein gp95/p97. J Exp Med 169 2 (1989) 585-590
6. Li G., Miles A., Line A., and Rees R.C. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 53 3 (2004) 139-143
7. Tureci O., Sahin U., and Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 3 8 (1997) 342-349
8. Scanlan M.J., Chen Y.T., Williamson B., Gure A.O., Stockert E., Gordan J.D., et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76 5 (1998) 652-658
9. Lee S.Y., Obata Y., Yoshida M., Stockert E., Williamson B., Jungbluth A.A., et al. Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA 100 5 (2003) 2651-2656
10. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92 25 (1995) 11810-11813
11. Preiss S., Kammertoens T., Lampert C., Willimsky G., and Blankenstein T. Tumor-induced antibodies resemble the response to tissue damage. Int J Cancer 115 3 (2005) 456-462
12. Yang F., and Yang X.F. New concepts in tumor antigens: their significance in future immunotherapies for tumors. Cell Mol Immunol 2 5 (2005) 331-341
13. Nishikawa H., Tanida K., Ikeda H., Sakakura M., Miyahara Y., Aota T., et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci USA 98 25 (2001) 14571-14576
14. Klade C.S., Voss T., Krystek E., Ahorn H., Zatloukal K., Pummer K., et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1 7 (2001) 890-898
15. Miller J.C., Zhou H., Kwekel J., Cavallo R., Burke J., Butler E.B., et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3 1 (2003) 56-63
16. Gunawardana C.G., and Diamandis E.P. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 249 1 (2007) 110-119
17. Monach P.A., Meredith S.C., Siegel C.T., and Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 2 1 (1995) 45-59
18. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264 5159 (1994) 716-719
19. Pascolo S., Schirle M., Guckel B., Dumrese T., Stumm S., Kayser S., et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 61 10 (2001) 4072-4077
20. Skipper J.C., Hendrickson R.C., Gulden P.H., Brichard V., Van Pel A., Chen Y., et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183 2 (1996) 527-534
21. Hunt D.F., Henderson R.A., Shabanowitz J., Sakaguchi K., Michel H., Sevilir N., et al. Characterization of peptides bound to the class I MHC molecule HLA-A2,1 by mass spectrometry. Science 255 5049 (1992) 1261-1263
22. Boel P., Wildmann C., Sensi M.L., Brasseur R., Renauld J.C., Coulie P., et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2 2 (1995) 167-175
23. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J.J., De Plaen E., et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179 3 (1994) 921-930
24. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Sakaguchi K., Appella E., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91 14 (1994) 6458-6462
25. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 5038 (1991) 1643-1647
26. Coulie P.G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92 17 (1995) 7976-7980
27. Fijak M., and Meinhardt A. The testis in immune privilege. Immunol Rev 213 (2006) 66-81
28. Gotter J., Brors B., Hergenhahn M., and Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 199 2 (2004) 155-166
29. Cloosen S., Arnold J., Thio M., Bos G.M., Kyewski B., and Germeraad W.T. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res 67 8 (2007) 3919-3926
30. Yu Z., Theoret M.R., Touloukian C.E., Surman D.R., Garman S.C., Feigenbaum L., et al. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 114 4 (2004) 551-559
31. Ludewig B., Ochsenbein A.F., Odermatt B., Paulin D., Hengartner H., and Zinkernagel R.M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191 5 (2000) 795-804
32. Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2 9 (2001) 789-792
33. Grillo-Lopez A.J. (Rituximab Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 3 6 (2003) 767-779
34. Stoler D.L., Chen N., Basik M., Kahlenberg M.S., Rodriguez-Bigas M.A., Petrelli N.J., et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 96 26 (1999) 15121-15126
35. Tomlinson I., Sasieni P., and Bodmer W. How many mutations in a cancer?. Am J Pathol 160 3 (2002) 755-758
36. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450 7171 (2007) 893-898
37. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 5853 (2007) 1108-1113
38. Schietinger A., Philip M., Yoshida B.A., Azadi P., Liu H., Meredith S.C., et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314 5797 (2006) 304-308
39. Prehn R.T., and Main J.M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18 6 (1957) 769-778
40. Klein G., Sjogren H.O., Klein E., and Hellstrom K.E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20 (1960) 1561-1572
41. Kripke M.L. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 53 5 (1974) 1333-1336
42. Mumberg D., Wick M., and Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol 8 5 (1996) 289-293
43. Brandle D., Brasseur F., Weynants P., Boon T., and Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 183 6 (1996) 2501-2508
44. Dubey P., Hendrickson R.C., Meredith S.C., Siegel C.T., Shabanowitz J., Skipper J.C., et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 185 4 (1997) 695-705
45. Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., Loftus D., Appella E., et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183 3 (1996) 1185-1192
46. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269 5228 (1995) 1281-1284
47. Wang R.F., Wang X., Atwood A.C., Topalian S.L., and Rosenberg S.A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284 5418 (1999) 1351-1354
48. Cheever M.A., Chen W., Disis M.L., Takahashi M., and Peace D.J. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. Ann N Y Acad Sci 690 (1993) 101-112
49. Peace D.J., Chen W., Nelson H., and Cheever M.A. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 146 6 (1991) 2059-2065
50. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 5015 (1991) 49-53
51. Vogelstein B., and Kinzler K.W. p53 function and dysfunction. Cell 70 4 (1992) 523-526
52. Takenoyama M., Baurain J.F., Yasuda M., So T., Sugaya M., Hanagiri T., et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 118 8 (2006) 1992-1997
53. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117 6 (2007) 1466-1476
54. Chiari R., Foury F., De Plaen E., Baurain J.F., Thonnard J., and Coulie P.G. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 59 22 (1999) 5785-5792
55. Karanikas V., Colau D., Baurain J.F., Chiari R., Thonnard J., Gutierrez-Roelens I., et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 61 9 (2001) 3718-3724
56. Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102 44 (2005) 16013-16018
57. Zorn E., and Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 29 2 (1999) 592-601
58. Sensi M., and Anichini A. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res 12 17 (2006) 5023-5032
59. Sensi M., Nicolini G., Zanon M., Colombo C., Molla A., Bersani I., et al. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res 65 2 (2005) 632-640
60. Lozupone F., Rivoltini L., Luciani F., Venditti M., Lugini L., Cova A., et al. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 33 2 (2003) 556-566
61. Maeurer M.J., Gollin S.M., Martin D., Swaney W., Bryant J., Castelli C., et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98 7 (1996) 1633-1641
62. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., and Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66 4 (1996) 470-476
63. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99 25 (2002) 16168-16173
64. Wortzel R.D., Philipps C., and Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304 5922 (1983) 165-167
65. Wortzel R.D., Urban J.L., Philipps C., Fitch F.W., and Schreiber H. Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones. J Immunol 130 5 (1983) 2461-2466
66. Dudley M.E., and Roopenian D.C. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med 184 2 (1996) 441-447
67. Watts C., and Powis S. Pathways of antigen processing and presentation. Rev Immunogenet 1 1 (1999) 60-74
68. Abdel-Motal U.M., Berg L., Rosen A., Bengtsson M., Thorpe C.J., Kihlberg J., et al. Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur J Immunol 26 3 (1996) 544-551
69. Brigl M., and Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 22 (2004) 817-890
70. Cobb B.A., Wang Q., Tzianabos A.O., and Kasper D.L. Polysaccharide processing and presentation by the MHCII pathway. Cell 117 5 (2004) 677-687
71. Galli-Stampino L., Meinjohanns E., Frische K., Meldal M., Jensen T., Werdelin O., et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 57 15 (1997) 3214-3222
72. Haurum J.S., Arsequell G., Lellouch A.C., Wong S.Y., Dwek R.A., McMichael A.J., et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 180 2 (1994) 739-744
73. Haurum J.S., Hoier I.B., Arsequell G., Neisig A., Valencia G., Zeuthen J., et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 190 1 (1999) 145-150
74. Rudd P.M., Elliott T., Cresswell P., Wilson I.A., and Dwek R.A. Glycosylation and the immune system. Science 291 5512 (2001) 2370-2376
75. Speir J.A., Abdel-Motal U.M., Jondal M., and Wilson I.A. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 10 1 (1999) 51-61
76. Vlad A.M., Muller S., Cudic M., Paulsen H., Otvos Jr. L., Hanisch F.G., et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196 11 (2002) 1435-1446
77. Werdelin O., Meldal M., and Jensen T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc Natl Acad Sci USA 99 15 (2002) 9611-9613
78. Zeng Z., Castano A.R., Segelke B.W., Stura E.A., Peterson P.A., and Wilson I.A. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277 5324 (1997) 339-345
79. Kornfeld R., and Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54 (1985) 631-664
80. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1473 1 (1999) 67-95
81. Vlad A.M., and Finn O.J. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis 20 (2004) 73-79
82. Brockhausen I. Glycodynamics of mucin biosynthesis in gastrointestinal tumor cells. Adv Exp Med Biol 535 (2003) 163-188
83. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 52 (1989) 257-331
84. Kim Y.J., and Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 14 5 (1997) 569-576
85. Backlund J., Carlsen S., Hoger T., Holm B., Fugger L., Kihlberg J., et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 99 15 (2002) 9960-9965
86. Dzhambazov B., Holmdahl M., Yamada H., Lu S., Vestberg M., Holm B., et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur J Immunol 35 2 (2005) 357-366
87. Poschet J.F., Boucher J.C., Tatterson L., Skidmore J., Van Dyke R.W., and Deretic V. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc Natl Acad Sci USA 98 24 (2001) 13972-13977
88. Rhim A.D., Kothari V.A., Park P.J., Mulberg A.E., Glick M.C., and Scanlin T.F. Terminal glycosylation of cystic fibrosis airway epithelial cells. Glycoconj J 17 6 (2000) 385-391
89. Xia B., Royall J.A., Damera G., Sachdev G.P., and Cummings R.D. Altered O-glycosylation and sulfation of airway mucins associated with cystic fibrosis. Glycobiology 15 8 (2005) 747-775
90. Vogt G., Chapgier A., Yang K., Chuzhanova N., Feinberg J., Fieschi C., et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 37 7 (2005) 692-700
91. Ju T., and Cummings R.D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437 7063 (2005) 1252
92. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491 (2001) 369-402
93. Spiro R.G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12 4 (2002) 43R-56R
94. Dennis J.W., Laferte S., Waghorne C., Breitman M.L., and Kerbel R.S. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236 4801 (1987) 582-585
95. Sell S. Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol 21 10 (1990) 1003-1019
96. Fernandes B., Sagman U., Auger M., Demetrio M., and Dennis J.W. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 51 2 (1991) 718-723
97. Seelentag W.K., Li W.P., Schmitz S.F., Metzger U., Aeberhard P., Heitz P.U., et al. Prognostic value of beta1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res 58 23 (1998) 5559-5564
98. Murata K., Miyoshi E., Ihara S., Noura S., Kameyama M., Ishikawa O., et al. Attachment of human colon cancer cells to vascular endothelium is enhanced by N-acetylglucosaminyltransferase V. Oncology 66 6 (2004) 492-501
99. Springer G.F. T and Tn, general carcinoma autoantigens. Science 224 4654 (1984) 1198-1206
100. Yuan M., Itzkowitz S.H., Boland C.R., Kim Y.D., Tomita J.T., Palekar A., et al. Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry. Cancer Res 46 9 (1986) 4841-4847
101. Itzkowitz S.H., Yuan M., Montgomery C.K., Kjeldsen T., Takahashi H.K., Bigbee W.L., et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 49 1 (1989) 197-204
102. Itzkowitz S.H., Yuan M., Fukushi Y., Palekar A., Phelps P.C., Shamsuddin A.M., et al. Lewisx- and sialylated Lewisx-related antigen expression in human malignant and nonmalignant colonic tissues. Cancer Res 46 5 (1986) 2627-2632
103. Tozawa K., Okamoto T., Kawai N., Hashimoto Y., Hayashi Y., and Kohri K. Positive correlation between sialyl Lewis X expression and pathologic findings in renal cell carcinoma. Kidney Int 67 4 (2005) 1391-1396
104. Ono M., and Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J 20 1 (2004) 71-78
105. Iwamoto S., Withers D.A., Handa K., and Hakomori S. Deletion of A-antigen in a human cancer cell line is associated with reduced promoter activity of CBF/NF-Y binding region, and possibly with enhanced DNA methylation of A transferase promoter. Glycoconj J 16 10 (1999) 659-666
106. Rosen S.D., and Bertozzi C.R. The selectins and their ligands. Curr Opin Cell Biol 6 5 (1994) 663-673
107. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., and Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98 6 (2001) 3352-3357
108. Kim Y.J., Borsig L., Varki N.M., and Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 95 16 (1998) 9325-9330
109. Livingston P.O. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 6 6 (1995) 357-366
110. Livingston P.O., Hood C., Krug L.M., Warren N., Kris M.G., Brezicka T., et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 54 10 (2005) 1018-1025
111. Livingston P.O., and Ragupathi G. Cancer vaccines targeting carbohydrate antigens. Hum Vaccin 2 3 (2006) 137-143
112. Livingston P.O., Zhang S., and Lloyd K.O. Carbohydrate vaccines that induce antibodies against cancer 1. Rationale. Cancer Immunol Immunother 45 1 (1997) 1-9
113. Sabbatini P.J., Ragupathi G., Hood C., Aghajanian C.A., Juretzka M., Iasonos A., et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 13 14 (2007) 4170-4177
114. Retter M.W., Johnson J.C., Peckham D.W., Bannink J.E., Bangur C.S., Dresser K., et al. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res 65 14 (2005) 6425-6434
115. Lloyd K.O., Burchell J., Kudryashov V., Yin B.W., and Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271 52 (1996) 33325-33334
116. Kontani K., Taguchi O., Narita T., Izawa M., Hiraiwa N., Zenita K., et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 84 9 (2001) 1258-1264
117. Gendler S., Taylor-Papadimitriou J., Duhig T., Rothbard J., and Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263 26 (1988) 12820-12823
118. Jankovic M.M., and Kosanovic M.M. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem 38 1 (2005) 58-65
119. Peracaula R., Tabares G., Royle L., Harvey D.J., Dwek R.A., Rudd P.M., et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 13 6 (2003) 457-470
120. Fukushima K., Ohkura T., Kanai M., Kuroki M., Matsuoka Y., Kobata A., et al. Carbohydrate structures of a normal counterpart of the carcinoembryonic antigen produced by colon epithelial cells of normal adults. Glycobiology 5 1 (1995) 105-115
121. Garcia M., Seigner C., Bastid C., Choux R., Payan M.J., and Reggio H. Carcinoembryonic antigen has a different molecular weight in normal colon and in cancer cells due to N-glycosylation differences. Cancer Res 51 20 (1991) 5679-5686
122. McNeel D.G., Nguyen L.D., Storer B.E., Vessella R., Lange P.H., and Disis M.L. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164 5 (2000) 1825-1829
123. Matsuura H., Takio K., Titani K., Greene T., Levery S.B., Salyan M.E., et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6, unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem 263 7 (1988) 3314-3322
124. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186 5 (1997) 645-653
125. Ward P.L., Koeppen H., Hurteau T., and Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 170 1 (1989) 217-232
126. Ju T., and Cummings R.D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci USA 99 26 (2002) 16613-16618
127. Piller V., Piller F., and Fukuda M. Biosynthesis of truncated O-glycans in the T cell line Jurkat localization of O-glycan initiation. J Biol Chem 265 16 (1990) 9264-9271
128. Freire T., Bay S., von Mensdorff-Pouilly S., and Osinaga E. Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression. Cancer Res 65 17 (2005) 7880-7887
129. Nakada H., Inoue M., Tanaka N., Numata Y., Kitagawa H., Fukui S., et al. Expression of the Tn antigen on T-lymphoid cell line Jurkat. Biochem Biophys Res Commun 179 2 (1991) 762-767
130. Kishikawa T., Ghazizadeh M., Sasaki Y., and Springer G.F. Specific role of T and Tn tumor-associated antigens in adhesion between a human breast carcinoma cell line and a normal human breast epithelial cell line. Jpn J Cancer Res 90 3 (1999) 326-332
131. Springer G.F. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 75 8 (1997) 594-602
132. Novak J., Julian B.A., Tomana M., and Mesteck J. Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol 21 5 (2001) 310-327
133. Berger E.G. Tn-syndrome. Biochim Biophys Acta 1455 2/3 (1999) 255-268
134. Felner K.M., Dinter A., Cartron J.P., and Berger E.G. Repressed beta-1,3-galactosyltransferase in the Tn syndrome. Biochim Biophys Acta 1406 1 (1998) 115-125
135. Saulsbury F.T. Henoch-Schonlein purpura. Curr Opin Rheumatol 13 1 (2001) 35-40
136. Piller V., Piller F., Klier F.G., and Fukuda M. O-Glycosylation of leukosialin in K562 cells, evidence for initiation and elongation in early Golgi compartments. Eur J Biochem 183 1 (1989) 123-135
137. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 14 (2001) 1031-1037